Sanofi US News

-- Focused effort to reach mothers, the family's "chief medical officer"

National AFib Education Campaign Launches to Help Improve the Care of People with This Serious and Increasingly Prevalent(1) Form of Irregular Heartbeat

- Weight gain was lowest in patients with baseline A1C below 8 percent and in patients 65 years and older -

- New phase III data from GetGoal-F1 study of once-daily lixisenatide support simplified treatment initiation -

Four local non-profits receive donations totaling more than $180,000

Positive impact from Genzyme on business EPS(1)

Greg Irace, Senior Vice President, Global Services

Early shipments of Fluzone and Fluzone High-Dose vaccines support health-care providers in immunization planning and provide additional opportunities to increase immunization rates

- Strategic Divestiture to focus on Growth Platforms in the United States and Canada -

Company has sponsored high school biotechnology competition for almost 20 years

- Data Presented at American Diabetes Association's 71st Annual Scientific Sessions -

- Once-Daily Lyxumia® Demonstrates Non-Inferior Reduction of Blood Glucose and Less Hypoglycemia versus Exenatide Twice Daily in Type 2 Diabetes Patients -

U.S. locations launch a “Walking Club” and promote a myriad of programs offered to employees to improve overall health and wellness

- Over 500 Million Patients Suffer from Hearing Loss Worldwide with No Currently Available Disease-Modifying Treatments -

Diabetes Co-Stars: Cook-Off Invites People to Share Diabetes-Friendly Recipes

Donation Helps Four-time NASCAR Cup Series Champion Jeff Gordon Shift Relief Efforts into High Gear

- Results of Phase III SAVE-ONCO study selected for "Best of ASCO 2011" -

U.S. locations launch a “Walking Club” and promote a myriad of programs offered to employees to improve overall health and wellness

Fluzone® Intradermal (Influenza Virus Vaccine) first to offer an immunization option with 90 percent smaller needle

- Indication Provides New Option to Help Protect Earlier Against Meningococcal Disease -

"AFib in America: State Impact Reports" Illustrate the Disconnect Between AFib's Impact and the Public Health Resources Available

The Coalition to Prevent DVT Promotes Education to Fill the Gap between DVT Risk and Co-Morbid Patients

Sanofi Pasteur stands shoulder to shoulder with Rotary International during NYSE and EURONEXT bell-ringing ceremonies

- WNBA, NBA Development League and NBA All-Star Dwight Howard, WNBA All-Star Alana Beard and NBA Legends Walt Frazier and Chris Dudley will also Raise Awareness about Diabetes -

Combination will enhance sanofi-aventis' sustainable growth strategy by expanding its footprint in biotechnology

- First industry partner for UCSF's Program for Breakthrough Biomedical Research (PBBR) -

- Collaboration promotes clinical and translational research to address unmet needs of cancer patients in India -

Final 10-year combination chemotherapy adjuvant survival data, studies of investigational agent iniparib to be featured at breast cancer symposium

Vaccine against one of the most common causes of hospital-acquired infection in North America & Europe tested in the U.S.

Investigational Intradermal Influenza Vaccine Induced Comparable Immune Responses to Licensed Fluzone Vaccine with Less Antigen, Smaller Injection Volume

- Focused on translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation -

World’s Largest Influenza Vaccine Producer Awarded $57 Million To Maintain Year-Round Egg Supply for Influenza Pandemic Planning

- Results of the Phase III TROPIC global study published -

Technology of in-vitro Models of the Human Immune System to Provide Competitive Advantage in Vaccine Development

Repeated Doctors Visits, ER Trips, and Admissions to Inpatient/Outpatient Facilities Create High Costs for Managing Patients with a Common, Complex Cardiovascular Disease

-'Diabetes Co-Stars' Offers Information and Support to People Living with Diabetes, Family and Friends -

- Findings Presented at European Association for the Study of Diabetes (EASD) 46th Annual Meeting -

- Phase III Study Results also demonstrated the therapy had acceptable safety profile -

Hundreds of thousands of doses of vaccine and medical supplies also provided

- Funding supports programs to advance personalized medicine -

- 1-vial Taxotere offers simplified preparation -

Early shipments support national goal to increase immunization rates

- Study Findings Presented at American Diabetes Association's 70th Annual Scientific Sessions -

- Study Results Presented at American Diabetes Association's 70th Annual Scientific Sessions -

- First and only therapy to provide significant survival benefit in second-line metastatic hormone-refractory prostate cancer -

- Alliance formed to advance cutting-edge research and foster collaboration between academia and industry -

- Sanofi-aventis Supports Consortium's Activities to Fund Promising Early-Stage Life Sciences Companies -

The licensed technology was developed by the NMRC with the help of the University of Colorado

Interactive Exhibit Unveiled at New Jersey's Liberty Science Center as it Embarks on Three-Year, 12-City Tour

Chattem Becomes the U.S. Consumer Healthcare Platform for sanofi-aventis

- Results observed in patients treated with cabazitaxel plus prednisone whose disease progressed despite prior docetaxel-based chemotherapy -

The Coalition to Prevent DVT Sends Awareness into Motion with an Educational Program Focusing on Preventative Care Through Movement

New Data Published by Journal of American Academy of Dermatology Demonstrated Sustained Efficacy Up to 25 Months

"AFib Support Team" Offers Insights on Comprehensive Approach to Management of Serious Heart Condition

Fluzone® High-Dose (Influenza Virus Vaccine) strengthens immune response in the 65+ population, an age group that suffers disproportionately from influenza and its complications

-- Combination Strengthens sanofi-aventis' Strategy to Accelerate Growth Through Innovation, Geographic Expansion and External Growth

Novel vaccine approach tested against one of the most common causes of hospital-acquired infection in Europe and North America

- Atul Dhir, M.D., Ph.D. has been appointed new BiPar CEO to continue growing entrepreneurial and innovative culture -

Final data confirm immunogenicity, safety profile

The two-dose meningococcal quadrivalent conjugate vaccine was generally well-tolerated

- Elitek is now approved to manage a potentially life-threatening complication associated with anti-cancer treatment in adults -

The first clinical trial data from America’s youngest vaccine recipients, children 6 months through 9 years of age, show the vaccine induces an immune response and is well-tolerated

Taking Control of Your Diabetes (TCOYD) Calls on Marketing Leaders and Creative Minds to "Start Taking Action Now for Diabetes"

Data from studies in adults 18 years of age and older provide confirmation that one dose of vaccine produces a robust immune response even in those over the age of 65 years

Women may delay treatment or seek injectable procedures

Company has now committed to produce 75.3 million doses of vaccine for the U.S. government